Germany's lower health technology assessment (HTA) IQWiG organises one-day conference to discuss with experts from universities, research institutes, industry and HTA bodies which criteria are important for assessing the credibility of health economic models. Special attention will be given to the cost-benefit analysis in the AMNOG procedure.
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.